-
1 Comment
ASIT Biotech S.A is currently in a long term uptrend where the price is trading 6.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, ASIT Biotech S.A gets an overall score of 2/5.
| Exchange | BR |
|---|---|
| CurrencyCode | EUR |
| ISIN | BE0974289218 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 5M |
|---|---|
| PE Ratio | None |
| Target Price | 3.8 |
| Dividend Yield | 0.0% |
| Beta | 1.33 |
ASIT Biotech S.A., a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium and internationally. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen rhinitis. The company is also developing hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy. ASIT Biotech S.A. was incorporated in 1997 and is based in Liege, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ASIT.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
